According to a new report, published by KBV research, The Global Insomnia Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.
The Hospital market acquired the maximum revenue share in the Global Insomnia Market by Distribution Channel in 2021, thereby, achieving a market value of $3.4 billion by 2028. The number people dealing with sleeping disorder is rising all over the world. In a large number of cases, the patient may need to be admitted to the hospital for treatment of a condition brought on by the insomnia if sleep deprivation causes an accident or other physical harm. As a result, the insomnia market would grow in this segment.
The Non-Pharmacological market is showcasing a CAGR of 7.1% during (2022 - 2028). Due to rising demand for yoga & cognitive behavioral therapy, as well as improvements in healthcare technology, the market is anticipated to expand in this segment. The following hypnosis as the top recommended therapy for insomnia patients is CBTI (Cognitive Behavioral Therapy for Insomnia), which can be used with a variety of techniques to help doctors better understand & treat their patients.
The North America market dominated the Global Insomnia Market by Region in 2021, thereby, achieving a market value of $2.1 Billion by 2028. The Europe market is showcasing a CAGR of 3.3% during (2022 - 2028). Additionally, The Asia Pacific market would generate a CAGR of 4.9% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/insomnia-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
By Distribution Channel
By Therapy Type
By Geography
Companies Profiled
Unique Offerings 
